Related Experiment Video
Updated: Aug 16, 2026
10:37
Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
Published on: November 30, 2016
Peppermint oil in irritable bowel syndrome
1Dr.Grigoleit@t-online.de
Summary
Enteric-coated peppermint oil (PO) effectively treats irritable bowel syndrome (IBS) symptoms, showing significantly higher success rates than placebo. It may be a first-choice treatment for IBS patients, improving their quality of life.
Area of Science:
- Gastroenterology
- Pharmacology
- Clinical Medicine
Background:
- Irritable bowel syndrome (IBS) is a common gastrointestinal disorder.
- Limited effective treatments exist for IBS symptoms.
- Peppermint oil (PO) has shown potential therapeutic benefits.
Purpose of the Study:
- To systematically review the efficacy and safety of enteric-coated peppermint oil (PO) for IBS.
- To compare PO with placebo and other IBS medications.
- To determine PO's potential as a first-line IBS treatment.
Main Methods:
- Literature search identifying 16 clinical trials with 651 patients.
- Included randomized double-blind cross-over, parallel-group, and open-label studies.
- Comparators included placebo (12 studies) and anticholinergics (3 studies).
Main Results:
- Eight of 12 placebo-controlled trials showed statistically significant benefits for PO.
- Average "overall success" rates were 58% for PO versus 29% for placebo.
- PO demonstrated comparable efficacy to anticholinergics with mild, transient side effects like heartburn.
Conclusions:
- Enteric-coated peppermint oil (PO) is an effective treatment for IBS symptoms.
- PO offers significant symptom improvement compared to placebo.
- PO may be considered a first-choice option for managing IBS, enhancing patient quality of life.
Related Concept Videos
01:23Irritable Bowel Syndrome
DefinitionIrritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by recurrent combinations of abdominal pain, bloating, diarrhea, or constipation.Pathophysiology of irritable bowel syndromeIts pathophysiology is multifactorial, involving disturbances in motility, sensory processing, microbial balance, barrier integrity, and gut–brain communication. These mechanisms interact to produce symptoms that vary across IBS subtypes.Altered Motility PatternsDisordered...
01:17Irritable Bowel Syndrome I: Introduction
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
01:30Irritable Bowel Syndrome III: Medical and Nursing Management
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
01:21Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are: